Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY

a technology of synthetic peptides and conjugates, which is applied in the field of conjugates comprised of polymer and synthetic peptides derived, can solve the problems of limiting the bioavailability of therapeutic agents, affecting the biological activity of therapeutic agents, so as to increase the biological half-life of synthetic peptides

Inactive Publication Date: 2010-01-21
TRIMERIS
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]There is provided, in accordance with the present invention, a conjugate comprising a polymer to which is attached two or more synthetic peptides derived from the HR region of gp41 (HR1 region, HR2 region, or a combination thereof), and which offers the advantages of retaining substantial biological activity (i.e., antiviral activity against HIV), and exhibiting durability (as compared to the synthetic peptide alone (e.g., without being part of a conjugate)). Other features, such as increasing the biological half-life of synthetic peptide which is part of the conjugate (e.g., enabling the synthetic peptide to survive longer in vivo before being degraded in and / or removed from the bloodstream as compared to synthetic peptide alone), will be apparent to one skilled in the art from the descriptions herein. The conjugate according to the present invention may further comprise a pharmaceutically acceptable carrier.

Problems solved by technology

However, as known to those skilled in the art (see, e.g., U.S. Pat. Nos. 6,258,774 and 6,113,906), such modifications to the therapeutic agent have inherent limitations, i.e. such modifications typically limit the bioavailability of the therapeutic agent.
More particularly, attaching a water-soluble polymer to a therapeutic agent, particularly a small peptide, frequently modulates the biological activity of the therapeutic agent in a deleterious manner.
While the prior art may teach conjugating therapeutic agents to a water-soluble polymer, the prior art fails to teach a conjugate comprising a polymer attached to two or more molecules of synthetic peptide, wherein the conjugate retains substantial bioactivity (e.g., retains substantial biological activity as compared to synthetic peptide alone), and durability (substantial biological activity against a strain of HIV-1 resistant to a synthetic peptide not in the form of a conjugate, as compared to that of the synthetic peptide).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY
  • CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY
  • CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0026]The embodiment illustrates a method of making the conjugates according to the present invention. One such method disclosed herein comprises the steps of: (a) reacting a first molecule of synthetic peptide with a polymer to form an intermediate comprising a first intermediate wherein the first molecule of synthetic peptide operably binds to a first reactive functionality of the polymer; (b) reacting the intermediate comprising a first intermediate with a second molecule of synthetic peptide to form a conjugate, wherein the second molecule of synthetic peptide operably binds to the intermediate comprising the first intermediate via a second reactive functionality of the polymer. It will be apparent to one skilled in the art that this method may also comprise adding a plurality of molecules of synthetic peptide simultaneously to a polymer, wherein more than one molecule of synthetic peptide becomes operably bound to the polymer in forming a conjugate, wherein each molecule of syn...

example 2

[0039]Illustrated in this example is the increased bioavailability (e.g., an extension of circulating half-life in vivo) of a conjugate according to the present invention as compared to the half-life of synthetic peptide alone. Using the methods and compositions taught in Example 1 herein, synthetic peptide and conjugate were produced. It is important to note that standard animal model for determining bioavailability has been correlated with the bioavailability of synthetic peptide in vivo in humans (as described in more detail in U.S. Pat. No. 6,258,782). Briefly, cannulated mice were dosed intravenously with either synthetic peptide, or a conjugate according to the present invention, with the dosing solution concentration being determined using the Edelhoch method, and as adjusted based on animal weight to achieve a 10 mg / kg dose. A sample of blood was removed at predetermined time intervals (0, 15, 30 min and 1, 2, 4, 6, and 8 hours) and added to collection tubes containing antic...

example 3

[0041]Illustrated in this example is the unexpected result of antiviral potency using the conjugates according to the present invention. In using an in vitro assay for demonstrating antiviral potency, it is important to note that antiviral effect of synthetic peptide demonstrated in the in vitro assay has been correlated with the antiviral effect of the synthetic peptide in vivo. In determining antiviral activity (e.g., one measure being the ability to inhibit transmission of HIV to a target cell) of the conjugates according to the present invention, used was an in vitro assay which has been shown, by data generated using synthetic peptides derived from either of the HR regions of HIV gp41, to be predictive of antiviral activity observed in vivo. More particularly, antiviral activity observed using an in vitro infectivity assay (“Magi-CCR5 infectivity assay”; see, e.g., U.S. Pat. No. 6,258,782) has been shown to reasonably correlate to antiviral activity observed in vivo for the sam...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightsaaaaaaaaaa
concentrationaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to application Ser. No. 10 / 671,282, filed Sep. 24, 2003, which claims the benefit of Provisional Application No. 60 / 414,439, filed Sep. 27, 2002, both of which are incorporated by reference herein in their entireties.FIELD OF THE INVENTION[0002]The present invention relates to conjugates comprised of polymer and synthetic peptides derived from Human Immunodeficiency Virus (HIV) gp41. More particularly, the present invention comprises a conjugate formed by operably binding to a polymer no less than two molecules of synthetic peptide comprising an amino acid sequence derived from either the HR1 region or the HR2 region of HIV-1 gp41.BACKGROUND OF THE INVENTION[0003]It is now well known that cells can be infected by HIV through a process by which fusion occurs between the cellular membrane and the viral membrane. The generally accepted model of this process is that the viral envelope glycoprotein complex (gp1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/16C12N7/02A61K38/10A61K38/16C07K7/08A61P31/18C07K7/00A61K38/00A61K47/48
CPCA61K38/00C12N2740/16122C07K14/005A61K47/48215A61K47/60A61P31/18A61K39/21A61K39/385C07K7/00C07K14/16
Inventor BRAY, BRIANKANG, MYUNG-CHOLTVERMOES, NICOLAIKINDER, DANIELLACKEY, JOHN WILLIAMZHANG, HUYI
Owner TRIMERIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products